產(chǎn)品目錄

規(guī)格	1mg 5mg 10mg
CAS	4135-11-9
別名	N/A
化學(xué)名	(S)-N-((S)-4-amino-1-(((2S,3R)-1-(((S)-4-amino-1-oxo-1-(((3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-((R)-1-hydroxyethyl)-12-isobutyl-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl)amino)butan-2-yl)a
分子式	C56H98N16O13
分子量	1203.5
溶解度	2 mg/ml in PBS (pH 7.2)
儲存條件	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request

產(chǎn)品描述：

Polymyxin B1 can bind and kill Gram-negative bacteria.

In view of the emergence of multidrug resistance among Gram-negative bacteria, polymyxin B has emerged as one of the therapeutic agents of last resort.

In vitro: Previous study reported the first molecular dynamics simulation investigation of the interaction of polymyxin B1 with complex models of membranes of E. coli. The results of >16 microseconds of simulation predicted that polymyxin B1 was probably to interact with the membranes via distinct mechanisms. Polymyxin B1 aggregated in the lipopolysaccharide headgroup region of the outer membrane with limited tendency for insertion within the lipid A tails. Whereas, polymyxin B1 readily insert into the inner membrane core, and the concomitant increased hydration might be responsible for bilayer destabilization and antimicrobial function [1].

In vivo: The PK parameters of the major components including polymyxin B1 from Polymyxin B did not appear to be significantly different. Less than 1% of the dose was recovered unchanged in urine collected over 48 h. Therapeutic drug concentrations maintained in kidney tissue at 48 h. The post-renal insufficiency to pre-renal insufficiency ratio of the area under the serum concentration-time curve from time zero to infinity was 1.33. Polymyxin B components seemed to have similar pharmacokinetics. Polymyxin B preferentially persisted in kidneys, suggesting a selective uptake process in renal cells [2].

Clinical trial: Treatment of patients with PMB1 has been shown to have adverse side effects on the renal and nervous system, and thus clinical use of PMB1 has been limited to topical treatment and “last resort” therapy of patients infected with multidrug-resistant bacteria or with chronic conditions who suffer from recurring respiratory infections [1].

特別提醒：

1. 本產(chǎn)品僅供科研使用。請勿用于醫(yī)藥、臨床診斷或治療，食品及化妝品等用途。請勿存放于普通住宅區(qū)。

2. 為了您的安全和健康，請穿好實(shí)驗(yàn)服并佩戴一次性手套和口罩操作。

原創(chuàng)作者：上海莼試生物技術(shù)有限公司

在線咨詢

留言注意事項(xiàng)：

1.遵守中華人民共和國有關(guān)法律、法規(guī)，尊重網(wǎng)上道德，承擔(dān)一切因您的行為而直接或間接引起的法律責(zé)任。

2.請您真實(shí)的反映產(chǎn)品的情況,不要捏造、誣蔑、造謠。如對產(chǎn)品有任何疑問,也可以留言咨詢。

3.未經(jīng)本站同意，任何人不得利用本留言簿發(fā)布個(gè)人或團(tuán)體的具有廣告性質(zhì)的信息或類似言論。

您感興趣的產(chǎn)品*
您的單位*
聯(lián)系人*
聯(lián)系電話*
詳細(xì)地址*
常用郵箱*
請輸入您對我們的意見或建議*
驗(yàn)證碼*